Burlington Industries, Inc. v. Dayco Corporation

849 F.2d 1418, 7 U.S.P.Q. 2d (BNA) 1158, 1988 U.S. App. LEXIS 7938, 1988 WL 59286
CourtCourt of Appeals for the Federal Circuit
DecidedJune 14, 1988
Docket88-1024
StatusPublished
Cited by84 cases

This text of 849 F.2d 1418 (Burlington Industries, Inc. v. Dayco Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Burlington Industries, Inc. v. Dayco Corporation, 849 F.2d 1418, 7 U.S.P.Q. 2d (BNA) 1158, 1988 U.S. App. LEXIS 7938, 1988 WL 59286 (Fed. Cir. 1988).

Opinion

NICHOLS, Senior Circuit Judge.

In this case the trial court has applied F.R.Civ.P. 56 to enter a summary judgment holding that Patent No. 4,283,455 (’455 patent) is unenforceable for inequitable conduct by the patent attorney or agent who applied for it. The court, however, denied summary judgment, as also sought on grounds of obviousness and noninfringement, but its decision on these issues may have been influenced by its interpretation of the patent respecting the dispositive issue. Burlington Industries, Inc., assignee of the patent, appeals and there is no cross-appeal as to the issues on which summary judgment was denied. The case is somewhat unusual in that the alleged misinformation supplied the examiner related to the invention itself, a supposed discrepancy being discovered, as to which no triable issue of fact existed, between the invention itself as it really was, and the invention as described in the application, an amendment thereto, and the patent as issued. Had the invention been truly described, the claims it is said would have read on the prior art. We vacate and remand because, reading the evidence as we must in the manner most favorable to the party opposing the motion, we do not perceive any showing of intent to deceive, such as our cases require, sufficient to eliminate any triable issue of fact. The evidence on the motion is, in our view, consistent with the innocent use of ambiguous language, such as perhaps a super lawyer would never be guilty of, but which all of us, being what we are, lapse into now and then.

Facts

The inventor, James N. McGee, an employee of the assignee Burlington, conceived and reduced to practice an improved V-belt cover fabric. He ran a bias-cut fabric through a thin solution of rubber polymer and conductive carbon black. He said he “impregnated the individual fibers in the yarn bundle.” Disclosure of April 23,1979. The patent attorney who prosecuted the patent application says * he understood the invention covered by the patent was to “impregnate the fiber bundles and encapsulate the individual fibers,” and it never occurred to him the patent he applied for would or could be read as claiming an ability to impregnate the individual fibers. To a lay reader it might appear, as it certainly did to the trial judge, that the two phrases mean something different, but the attorney says he and others unconsciously inserted the word “bundles” after the word “fiber.” The patent itself, summary, specifications, and claims, use both phrases with a fine impartiality. Moreover, no one asserts there was more than one invention: thus the correct full description of it must be one or the other and cannot be both, taken literally. The importance of the issue derives from the trial court’s belief that by claiming impregnation of individual fibers, the patent attorney avoided a prior art rejection which he at first confronted and which caused a Patent and Trademark Office (PTO) rejection of the first application.

In the “detailed description” we read: The continuous fabric strip 12 formed during slitting is then treated with a fluid mix of elastomeric polymeric material to impregnate in the yam bundles thereof and to encapsulate the individual fibers of such bundles with the polymeric material. [Col. 2, line 61.]

*1420 The numeral 12 refers to Fig. 1 of the patent which shows means to coat the belt by running it through a shallow dish containing the fluid mix 13. Here the inventor carefully avoids saying he impregnates the fibers. Yet he goes on:

The fluid mix 13 according to the present invention preferably has a low viscosity so that impregnation of the fibers is insured. [Col. 3, line 13.]

Later he reverts to the first formulation:

The purpose being to provide a solvent mix of suitable viscosity permitting effective yam bundle impregnation to coat the individual fibers. [Col. 3, line 43.] (* * * the present invention deliberately avoids dyeing in favor of coloring only the fiber surface by pigmenting.) Since each of the fibers of the present cover fabric is encapsulated with the impregnating polymeric material * * *. [Col. 5, line 19.]

Thus, the writer continuously shifts his phraseology while apparently under the impression he is saying the same thing. A like phenomenon occurs in the patent claims:

Claim 1 adopts once more the phraseology of the more careful formulation:
* * * [t]he individual fibers of said yams being encapsulated in a dried pigmented elastomeric polymer, * * *.
Claim 2 is dependent on Claim 1. Yet claim 3 declares:
[t]he fabric cover being produced from a continuous fabric strip by impregnating the individual fibers.
Claims 4 and 5 again impregnate “the individual fibers.” There follow some dependent claims, and Claims 12 and 13 again impregnate the fabric, while 16 impregnates the individual fibers once more.

In the original application, with 20 claims, a similar confusion is found — we say confusion if one assumes the inventor had made but one invention and that he knew, as he says, of no way a mix such as he described would impregnate the individual fibers if they were man made; also, if the mix did impregnate the individual fibers, the asserted advantage of white showing through, revealing the extent of wear, when the outer encapsulation wore off, would be lost. [Col. 1, line 62 to Col. 2, line 14.] The confusion could not possibly have been the product of any rejection by the examiner as it obtained in the file papers from the beginning.

Mr. Robert A. Vanderhye, the patent attorney who prosecuted the application, asserted in an affidavit that he used the shorter formulation, as illustrated in Claim 3 as “shorthand” for a “complicated concept.” He “unconsciously” inserted the word “bundles” after the word “fiber.” We do not have any explanation by the examiner of his mental attitude, but it is difficult to believe he did not share in the patent attorney’s mistake. He must be charged with notice of the actual contents of the patent, as issued with his approval, and it is difficult to believe he would not have noticed the confusion, and demanded a clarification, if he had ever consciously adverted to there being a difference in meaning between impregnating an individual fiber and impregnating a bundle. The trial court, after the controversy had arisen, and with tlj^ “20-20 vision of hindsight,” read the patent entirely differently than did those concerned with its issue, and we wonder how anybody skilled in patent law and practice could have generated such confusion without a sinister purpose. That is the fascinating puzzle this case presents.

Discussion

We start with the proposition that to sustain a motion for summary judgment the court must determine that there is no triable issue of material fact, because on the version most favorable to the party opposing the motion, that party still cannot prevail. Howes v. Medical Components, Inc., 814 F.2d 638, 643, 2 USPQ2d 1271, 1273 (Fed.Cir.1987); KangaROOS U.S.A., Inc. v. Caldor, Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Milwaukee Electric Tool Corp. v. Snap-On Inc.
271 F. Supp. 3d 990 (E.D. Wisconsin, 2017)
John Karczewski v. Dch Mission Valley LLC
862 F.3d 1006 (Ninth Circuit, 2017)
Front Row Technologies, LLC v. NBA Media Ventures, LLC
163 F. Supp. 3d 938 (D. New Mexico, 2016)
AstraZeneca UK Ltd. v. Aurobindo Pharma Ltd.
703 F.3d 511 (Federal Circuit, 2012)
Medisim Ltd. v. Bestmed LLC
910 F. Supp. 2d 591 (S.D. New York, 2012)
Therasense, Inc. v. Becton, Dickinson and Co.
649 F.3d 1276 (Federal Circuit, 2011)
Birchwood Laboratories, Inc. v. Battenfeld Technologies, Inc.
762 F. Supp. 2d 1152 (D. Minnesota, 2011)
Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc.
642 F. Supp. 2d 329 (D. Delaware, 2009)
Medical Components, Inc. v. Arrow International, Inc.
646 F. Supp. 2d 714 (E.D. Pennsylvania, 2009)
Eisai Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
629 F. Supp. 2d 416 (D. New Jersey, 2009)
Dickson Industries, Inc. v. Patent Enforcement Team, L.L.C.
333 F. App'x 514 (Federal Circuit, 2009)
Probert v. Clorox Co.
258 F.R.D. 491 (D. Utah, 2009)
Bowling v. Hasbro, Inc.
582 F. Supp. 2d 192 (D. Rhode Island, 2008)
Aventis Pharma S.A. v. Amphastar Pharmaceuticals, Inc.
525 F.3d 1334 (Federal Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
849 F.2d 1418, 7 U.S.P.Q. 2d (BNA) 1158, 1988 U.S. App. LEXIS 7938, 1988 WL 59286, Counsel Stack Legal Research, https://law.counselstack.com/opinion/burlington-industries-inc-v-dayco-corporation-cafc-1988.